cilostazol has been researched along with 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-(3-pyridylmethylamino)-3(2h)-pyridazinone hydrochloride in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asakura, Y; Hori, M; Ishiwata, N; Ito, Y; Kawanishi, M; Mitani, A; Nakaike, S; Nishiyama, H; Noguchi, K; Shudo, N; Takahashi, K; Takahashi, S; Tsuruzoe, N | 1 |
1 other study(ies) available for cilostazol and 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-(3-pyridylmethylamino)-3(2h)-pyridazinone hydrochloride
| Article | Year |
|---|---|
NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model.
Topics: Animals; Body Temperature; Cilostazol; Hindlimb; Humans; Intermittent Claudication; Male; Phosphodiesterase Inhibitors; Platelet Aggregation; Pyridazines; Rats; Rats, Wistar; Tetrazoles; Vasodilation; Walking | 2007 |